Abbonarsi

Intestinal permeability and gut microbiota interactions of pharmacologically active compounds in valerian and St. John’s wort - 29/04/23

Doi : 10.1016/j.biopha.2023.114652 
Antoine Chauveau a, Andrea Treyer a, Annelies Geirnaert b, Lea Bircher b, Angela Babst b, Vanessa Fabienne Abegg a, Ana Paula Simões-Wüst c, Christophe Lacroix b, Olivier Potterat a, , Matthias Hamburger a,
a Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland 
b Laboratory of Food Biotechnology, Institute of Food, Nutrition and Health, Department of Health Science and Technology, ETH Zurich, Zurich, Switzerland 
c Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland 

Correspondence to: Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of BaselKlingelbergstrasse 50Basel4056Switzerland

Abstract

Phytomedicines such as valerian and St. John’s wort are widely used for the treatment of sleeping disorders, anxiety and mild depression. They are perceived as safe alternatives to synthetic drugs, but limited information is available on the intestinal absorption and interaction with human intestinal microbiota of pharmacologically relevant constituents valerenic acid in valerian, and hyperforin and hypericin in St. John’s wort. The intestinal permeability of these compounds and the antidepressant and anxiolytic drugs citalopram and diazepam was investigated in the Caco-2 cell model with bidirectional transport experiments. In addition, interaction of compounds and herbal extracts with intestinal microbiota was evaluated in artificial human gut microbiota. Microbiota-mediated metabolisation of compounds was assessed, and bacterial viability and short-chain fatty acids (SCFA) production were measured in the presence of compounds or herbal extracts. Valerenic acid and hyperforin were highly permeable in Caco-2 cell monolayers. Hypericin showed low-to-moderate permeability. An active transport process was potentially involved in the transfer of valerenic acid. Hyperforin and hypericin were mainly transported through passive transcellular diffusion. All compounds were not metabolized over 24 h in the artificial gut microbiota. Microbial SCFA production and bacterial viability was not substantially impaired nor promoted by exposure to the compounds or herbal extracts.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Intestinal permeability was assessed with a validated Caco-2 cell model.
Gut microbiota interactions were investigated with the PolyfermS system.
Valerenic acid, hyperforin, diazepam, and citalopram were highly permeable.
Hypericin was low-to-moderately permeable.
Compounds were not metabolized by the microbiota and did not impact their viability.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Valerenic acid, Hyperforin, Hypericin, Caco-2 cells, Gut microbiota, Short-chain fatty acids


Mappa


© 2023  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 162

Articolo 114652- giugno 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Eicosapentaenoic acid (EPA) reduces pulmonary endothelial dysfunction and inflammation due to changes in protein expression during exposure to particulate matter air pollution
  • Samuel C.R. Sherratt, Peter Libby, Hazem Dawoud, Deepak L. Bhatt, Tadeusz Malinski, R. Preston Mason
| Articolo seguente Articolo seguente
  • Diesel vehicles-derived PM2.5 induces lung and cardiovascular injury attenuates by Securiniga suffruticosa: Involvement of NF-κB-mediated NLRP3 inflammasome activation pathway
  • Byung Hyuk Han, Se Hoon Jang, Youn Jae Jang, Se Won Na, Jung Joo Yoon, Hi Gyu Moon, Soo Yeon Kim, Chang Seob Seo, Ho Sub Lee, Young Mi Lee, Dae Gill Kang, Yun Jung Lee

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.